Abstracts

178 – Maintenance of HIV Suppression at 12 Months With VH3810109 (N6LS) Q4M + CAB LA QM: The EMBRACE Study

Background VH3810109 (N6LS) is a broadly neutralizing CD4-binding site antibody in development for ultra-long-acting HIV-1 treatment. The EMBRACE study evaluated efficacy, safety, and tolerability of N6LS every 4 months (Q4M) + monthly intramuscular long-acting cabotegravir (CAB LA) to maintain HIV-1 suppression. Month 6 results showed that intravenous (IV) and subcutaneous (SC) N6LS regimens maintained virologic…

179 – Safety and Antiviral Effect of 10E8.4/Ibalizumab in People With HIV: A Phase Ib Trial

Background Broadly-neutralizing antibodies (bNAbs) show promise for HIV prevention and treatment. The bispecific antibody 10E8.4/ibalizumab (10E8.4/iMab) has arms that target the HIV-1 envelope membrane proximal external region (10E8.4) and the CD4 receptor on host cells (iMab). It has broad and potent in vitro HIV neutralization ability. We conducted a phase 1b, open label trial of…

180 – Sustained DNA-Encoded SARS-CoV-2 Antibody Expression and Safety Through 96 Weeks

Background DNA-encoded monoclonal antibodies (DMAbs) offer a potential long-acting, cold-chain–independent alternative to recombinant antibody delivery. Prior reports established durable in vivo expression through week 72. We now present extended follow-up to week 96, the longest reported for any DMAb clinical trial. Methods In this Phase 1, open-label, dose-escalation study (NCT05293249), healthy adults received intramuscular injections…

182 – HIV Testing and Treatment Gaps in Subgroups of Men With HIV: Insights From 7 African countries

Background Men in eastern and southern Africa (ESA) have larger gaps in achieving the UNAIDS 95-95-95 care cascade (91% status aware, 79% treated, 74% virally suppressed) than women (95%-87%-82%). We describe these gaps (unaware, untreated, unsuppressed) among subgroups of men with HIV (MWH) in seven ESA countries. Methods We pooled data from nationally representative Population-based…

185 – Effects of a Coping Intervention on Viral Load Among South African Women With HIV and Sexual Trauma

Background South African women living with HIV (WLH) report disproportionately higher levels of sexual trauma and related stress, which compromises care engagement and adherence. This randomized clinical trial examined the effectiveness of Improving AIDS Care after Trauma (ImpACT+), a task-shared, trauma-focused coping intervention, in promoting viral suppression and reductions in trauma among WLH initiating antiretroviral…

187 – Early Findings From Cabotegravir Injectable HIV PrEP Rollout in Malawi: Uptake and Continuation

Background Malawi introduced 2-monthly long-acting injectable cabotegravir (CAB LA) for HIV pre-exposure prophylaxis (PrEP) in March 2024 to improve continued use and effectiveness compared to oral PrEP. The PathToScale initiative, led by Government of Malawi, with support of a consortium of partners, supported initial enrollment of clients onto CAB LA as part of the initiative’s…

188 – Randomised Pilot of Pharmacy-Based Collection of PrEP Refills Among Female Sex Workers in Zimbabwe

Background Oral PrEP continuation/retention among sex workers (SW) is poor. Pharmacy-based PrEP refills have potential to improve continuation. We report on 12 12-month continuation from the pilot of a pharmacy-based PrEP refill intervention called Together Optimizing PrEP Access in Zimbabwe (TOPAZ). Methods TOPAZ was nested in the nationally scaled Key Populations (KP) program that provides…

190 – Declining HIV Incidence and Differential PrEP Effectiveness Among Key Populations With STIs, 2014-25

Background HIV preexposure prophylaxis (PrEP) is a highly efficacious intervention. Data on PrEP’s population-level effectiveness, how it may be changing over time, and how it varies in different populations are more limited. We evaluated the population-level effectiveness of PrEP among cisgender men and transgender and nonbinary people who have sex with men (MSM/TNB) with bacterial…

192 – HIV Incidence in a Nationwide Cohort of Transgender Women in the United States and Puerto Rico

Background Transgender (trans) women are disproportionately impacted by HIV and prioritized in the National HIV/AIDS Strategy 2022-2025 in the US. However, shifting federal priorities, erasure of gender identity data collection, and escalating political attacks on trans communities threaten to undermine progress in the HIV response. This study addresses epidemiologic gaps by evaluating HIV incidence in…